181 F. Supp. 3d 278
E.D. Pa.2016Background
- MDL bellwether: wrongful-death/products-liability suit alleging acetaminophen (Extra Strength Tylenol) caused acute liver failure at or near recommended dosing; multiple consolidated cases in MDL.
- Defendants filed 18 motions in limine challenging admission of categories of evidence (AERs, FDA interactions, advisory-committee materials, marketing, financials, foreign labeling, etc.).
- Central disputed themes: notice/knowledge, causation, design/warning defect, corporate state of mind, and punitive-motive evidence.
- Court applied FRE 401/402/403 relevance and prejudice framework and reserved many context-specific hearsay rulings for trial.
- Court excluded expert testimony that would opine directly on defendants’ corporate state of mind or legal conclusions; allowed many categories for limited uses (notice, knowledge, impeachment) subject to trial objections.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Adverse Event Reports (AERs) admissibility | AERs show notice, may be used non-hearsay or via exceptions; experts may rely on them | AERs are unreliable hearsay/unsuitable for expert reliance | Denied (without prejudice): AERs admissible to show notice; hearsay/Daubert issues deferred to trial/Daubert rulings |
| Fraud on the FDA evidence | Evidence of misleading FDA communications shows knowledge, state of mind, and is relevant to claims (not a Buckman claim) | Buckman preempts fraud-on-the-FDA evidence; such evidence is barred | Denied: Buckman does not bar evidence showing state of mind/knowledge; cannot base liability solely on FDA non-disclosure |
| FDA Advisory Committee materials (2002, 2009) | Materials show the agency and industry awareness of hepatotoxicity risk at or near 4g/day and fasting risk factors; relevant to notice | Materials are hearsay, confusing, prejudicial, non-binding recommendations | Denied (without prejudice): admissible at least to show notice/knowledge; hearsay/403 context-specific rulings at trial |
| Expert testimony about corporate state of mind | Experts can explain industry practices and decision context | Experts would usurp jury by opining on intent/knowledge (legal conclusion) | Granted (without prejudice): experts cannot state legal conclusions about corporate state of mind; may present facts that allow jury inference |
| Draft/internal, non-disseminated documents | Show what defendants knew internally and their state of mind | Irrelevant if no reliance by decedent/physicians; unduly prejudicial | Denied (without prejudice): admissible to show knowledge/motive; 403 analysis deferred to trial |
| Manufacturing/QC issues, FDA Form 483s, Consent Decree, Plea Agreement | Relevant to motive, knowledge, and impeachment | Irrelevant to design-defect case; highly prejudicial character evidence; hearsay | Granted in part / Denied in part: pharmacovigilance-related 483 findings admissible; 2011 Consent Decree & 2015 Plea Agreement excluded; manufacturing-defect evidence excluded unless defendants open the door |
| Marketing/promotional materials and financials | Relevant to consumer perceptions, adequacy of warnings, state of mind, and motive (profit over safety) | Irrelevant, prejudicial, or admissible only if seen by decedent; financials improperly invite wealth-based sympathy | Marketing: Denied (without prejudice) — admissible for notice/context/motive; Financials: granted in part — net worth excluded under Alabama law, other financial metrics reserved and may be admitted in limited form |
| Foreign labeling and regulatory actions | Foreign labels/regulatory actions show defendant knowledge and notice | Foreign regimes differ; labels are irrelevant/hearsay and may confuse jury | Denied (without prejudice): foreign labels may be admissible to show notice/knowledge with contextual foundation; not admissible to prove breach of U.S. duty without proper context |
Key Cases Cited
- Sprint v. Mendelsohn, 552 U.S. 379 (district court given wide discretion on evidence admissibility)
- U.S. v. Abel, 469 U.S. 45 (district court discretion on evidence)
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (fraud-on-the-FDA claims impliedly preempted)
- Wyeth v. Levine, 555 U.S. 555 (federal law does not bar state-law failure-to-warn claims; FDA compliance not an absolute defense)
- Barker v. Deere & Co., 60 F.3d 158 (3d Cir.) (prior incidents admissible if substantially similar; need foundation)
- Berckeley Inv. Grp., Ltd. v. Colkitt, 455 F.3d 195 (3d Cir.) (experts cannot render legal conclusions)
- Benedi v. McNeil-P.P.C., Inc., 66 F.3d 1378 (4th Cir.) (AERs admissible to prove notice)
- Decker v. GE Healthcare Inc., 770 F.3d 378 (6th Cir.) (experts may reliably testify about significance of AERs)
- Horn v. Thoratec Corp., 376 F.3d 163 (3d Cir.) (discusses deference to FDA in preemption context)